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1. Introduction 
The development of effective chemotherapy has greatly improved survival among patients 
with breast cancer, although molecular cancer therapeutics is also emerging as an important 
approach. Molecular-targeting therapy using agents such as trastuzumab has enhanced 
breast cancer treatment, while clinical trials have suggested that epidermal growth factor 
receptor (EGFR), vascular endothelial growth factor (VEGF), and mammalian target of 
rapamycin (mTOR) are potential targets. Our current efforts to identify molecular targets 
that might be useful for treatment are focused on two molecules: the putative metastasis-
suppressor gene Cap43/NDRG1/Drg-1 (Cap43) protein and the Y-box binding protein-1 
(YB-1). Here we describe the latest preclinical and clinical developments in molecular-
targeting therapeutic strategies for breast cancer, including those using Cap43 and YB-1. 
2. Current study of molecular-targeting agents 
2.1 EGFR family signaling 
The EGFR family of receptor tyrosine kinases is an attractive target for anticancer strategies. 
Members include EGFR, which is also known as human epidermal growth factor receptor 1 
(HER1), HER2 (erbB2), HER3 (erbB3), and HER4 (erbB4). Through their interconnected 
cellular signaling network, EGFR family members regulate diverse biological processes 
including cell proliferation, differentiation, and survival. They also play key roles in the 
development and progression of breast cancer. High levels of EGFR and HER2 expression 
have been reported in 15–30% of breast cancers, and are correlated with poor prognosis ( 
Schlotter et al., 2008; Witton et al., 2003). HER3 expression, observed in 18% of tumors, is 
correlated with reduced overall survival (OS) and it may provide a rout for resistance to 
agents targeting EGFE or HER2 (Koutras et al., 2010; Witton et al., 2003). By contrast, HER4 
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expression, observed in 12% of tumors, is associated with differentiation and growth 
inhibition, thus it is more consistently related with favorable prognosis in breast cancer 
(Koutras et al., 2010; Witton et al., 2003). EGFRs have an extracellular domain involved in 
ligand binding, a helical transmembrane segment, and an intracellular protein kinase 
domain. Upon ligand binding, the extracellular domain undergoes conformational changes 
that allow EGFR family members to form homodimers or heterodimers. Particularly, the 
combination of HER2 and HER3 receptors may be critical in breast cancer growth and 
progression. Ligand binding induces dimerization of the receptor and activation of the 
kinase through autophosphorylation, stimulating phosphoinositide 3-kinase (PI3K)/Akt 
and mitogen-activated protein kinase (MAPK) signaling. This is followed by proliferation, 
migration, adhesion, and angiogenesis (Atalay et al., 2003; Lin & Winer, 2004; Rosen et al., 
2010; Russo & Ove, 2003; Schlotter, 2008).  
2.2 EGFR family-targeted therapies 
2.2.1 Trastuzumab 
Targeting signaling has led to the development of therapies that reduce the activation of 
HER2 in breast cancer. Trastuzumab is a humanized monoclonal antibody that targets the 
extracellular domain of the transmembrane tyrosine kinase HER2, and is a key drug in the 
treatment strategy for HER2-positive breast cancer. National Comprehensive Cancer 
Network (NCCN) guidelines recommend both trastuzumab monotherapy and combined 
trastuzumab and chemotherapy as first-line treatments for metastatic breast cancer (MBC) 
(NCCN 2011), and these have both shown efficacy in HER2-positive MBC patients (Slamon 
et al., 2001;  Vogel et al., 2002). Data from the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-31 + North Central Cancer Treatment Group (NCCTG) N9831 trial, the 
HERceptin Adjuvant (HERA) trial, the Breast Cancer International Research Group (BCIRG) 
006 trial, and the Finland Herceptin (FinHer) trial (Joensuu et al., 2006; Perez et al., 2007; 
Slamon et al., 2006; Smith et al., 2007) have suggested that adjuvant trastuzumab treatment 
improves both disease-free survival (DFS) and OS among early breast cancer patients. 
NCCN guidelines and the St Gallen consensus guidelines therefore recommend that 
adjuvant trastuzumab treatment should be used for node-positive and node-negative, high-
risk early HER2-positive breast cancer patients (NCCN 2011; Goldhirsch et al., 2009). The 
efficacy of adjuvant trastuzumab therapy for HER2-positive breast cancer patients with a 
tumor size of less than 1 cm is unclear. Gonzalez-Angulo et al. reported that such patients 
who were HER2-positive had higher risks of recurrence and distant recurrence than those 
who were HER2-negative. These results suggest that patients with HER2-positive 
T1abN0M0 tumors have a significant risk of relapse and should be considered for 
trastuzumab adjuvant therapy (Gonzalez-Angulo et al., 2009). A retrospective analysis of the 
effect of adjuvant trastuzumab in patients with small, node-negative, HER2-positive breast 
cancer was reported at the 2010 American Society of Clinical Oncology (ASCO) meeting. 
This concluded that even small breast cancers probably derive significant benefit from 
adjuvant trastuzumab therapy (McArthur et al., 2010). The NeOAdjuvant Herceptin 
(NOAH) trial (Gianni et al., 2010a) was a randomized study that evaluated the addition of 
trastuzumab to anthracycline- and taxane-based chemotherapy for patients with HER2-
positive locally advanced breast cancer in a neoadjuvant setting. Trastuzumab was well 
tolerated, and significantly improved the 3-year event-free survival (EFS) of patients with 
HER2-positive breast cancer (71% with trastuzumab vs 56% without trastuzumab, p=0.013). 
The addition of trastuzumab to neoadjuvant chemotherapy should therefore be considered 
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for women with HER2-positive, locally advanced or inflammatory breast cancer in order to 
improve the EFS, survival, and clinical and pathological tumor responses. 
2.2.2 Trastuzumab-DM1 (T-DM1) 
T-DM1 is an antibody–drug conjugate that uses trastuzumab to deliver the maytansinoid 
antimicrotubule agent DM1 specifically to HER2-positive cells. T-DM1 was previously 
shown to be well tolerated with no dose-limiting cardiotoxicity, with an objective response 
rate by independent assessment of 25.9%, and a median progression-free survival (PFS) time 
of 4.6 months (Burris et al., 2011). These results suggest that T-DM1 monotherapy is useful 
in patients with heavily pretreated, HER2-positive MBC. 
2.2.3 Pertuzumab 
HER2-containing heterodimers elicit greater mitogenic responses than HER2 homodimers. 
The ligand-induced activation of either HER1 or HER3, and the subsequent formation of 
heterodimers with HER2, might therefore play an important role in resistance to 
conventional HER2 inhibitors. Pertuzumab is a humanized monoclonal antibody and a 
member of a new class of inhibitors, including EGFR family members such as HER3, that 
block HER2 dimerization, thereby inhibiting the downstream signaling processes associated 
with tumor growth and progression (Adams et al., 2006; Franklin et al., 2004). Clinical 
studies have indicated that pertuzumab monotherapy shows limited efficacy for HER2-
positive or HER2-negative advanced breast cancer (Cortes et al., 2009; Gianni et al., 2010b). 
Trastuzumab and pertuzumab bind to distinct epitopes on the HER2 extracellular domain, 
and it has been hypothesized that a combination of the two agents might inhibit tumor 
growth more effectively than either agent alone (Franklin et al., 2004; Hubbard, 2005). 
Indeed, in vivo data showed that the combination had a strongly enhanced antitumor effect 
and induced tumor regression in breast cancer xenograft models, which was not achieved 
by either agent alone (Scheuer et al., 2009). In view of this synergistic effect, a phase II trial 
of pertuzumab and trastuzumab combination therapy in patients with HER2-positive MBC 
was performed. The objective response rate (ORR) was 24.2% and the clinical benefit rate 
(CBR) 50%. The combination was active and well tolerated in patients who had experienced 
progression during previous trastuzumab therapy (Baselga et al., 2010a). A phase Ib/II trial 
of T-DM1 with pertuzumab combination therapy for locally advanced or MBC was also 
reported, and nine partial responses (PRs) were observed among 23 patients (Miller et al., 
2010). Due to the safety, tolerability, and efficacy of full-dose T-DM1 plus pertuzumab, this 
approach is a promising new treatment strategy for MBC. In addition, the ongoing, 
randomized, phase II Pertuzumab HERceptin Evaluation with XelodA (PHEREXA) study 
will evaluate the efficacy and safety of a combination of trastuzumab and capecitabine with 
or without pertuzumab in patients with HER2-positive MBC (ClinicalTrials.gov 1). 
Pertuzumab and trastuzumab combination therapy was also investigated in The 
Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation 
(NeoSphere) trial, which was a phase II clinical study of preoperative systemic therapy that 
ranked the antitumor activity and tolerability of the following combinations: 
trastuzumab+docetaxel, docetaxel+trastuzumab+pertuzumab, trastuzumab+pertuzumab, 
and docetaxel+pertuzumab. The clinical CR+PR rates were 80%, 88%, 68%, and 71%, 
respectively, while pathologic complete response (pCR) rates were 29%, 45.8%, 17.8%, and 
24%, respectively (Gianni et al., 2010c). These data showed superior antitumor activity in the 
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docetaxel+trastuzumab+pertuzumab group. Notably, the trastuzumab+pertuzumab group 
also showed excellent tolerability and effective antitumor activity, which is expected to lead 
to the establishment of molecular-targeting therapy that does not involve toxic 
chemotherapy. 
2.3 Tyrosine kinase inhibitors 
2.3.1 Lapatinib 
Lapatinib is an oral small-molecule tyrosine kinase inhibitor that reversibly inhibits both 
EGFR and HER2 (Lackey, 2006). Binding of EGFR ligands to EGFR stimulates 
heterodimerization with HER2 and activation of downstream signaling pathways including 
PI3K, Akt protein kinase, and mTOR, resulting in an increase in cell proliferation. 
Phosphatase and tensin homolog (PTEN) has tumor-suppressor activity in this signaling 
pathway, and loss of PTEN, as well as up-regulation of insulin-like growth factor 1 receptor 
(IGF-1R) signaling, is associated with trastuzumab resistance. Lapatinib blocks the 
activation of the HER2 signaling pathway by inhibiting the intracellular tyrosine kinase of 
EGFR and HER2, and Lapatinib is believed to circumvent the trastuzumab resistance 
associated with the up-regulation of IGF-1R signaling. Lapatinib also binds to the p95 
truncated variant of HER2 (p95 HER2) and inhibits cell proliferation in trastuzumab-
resistant cells expressing p95 HER2. This suggests that lapatinib is a potential therapeutic 
for breast cancer patients who are resistant to trastuzumab (Vogel et al., 2010). In a phase II 
clinical trial (EGF20009), lapatinib monotherapy demonstrated clinical activity and was well 
tolerated as a first-line therapy in HER2-amplified locally advanced or MBC (Gomez et al., 
2008). In a randomized phase III study, patients with HER2-positive MBC that had 
progressed after treatment with anthracycline, taxane, and trastuzumab were given 
combination therapy with lapatinib and capecitabine. The performance of this was superior 
to capecitabine alone, with no increase in serious toxic effects (Geyer et al., 2006). A phase III 
randomized study comparing lapatinib alone with lapatinib plus paclitaxel as first-line 
treatment for MBC also found that the combination therapy significantly improved clinical 
outcomes in HER2-positive patients (Di Leo et al., 2008). Preclinical studies have shown that 
lapatinib is active not only as a monotherapy but also in combination with trastuzumab 
(Konecny et al., 2006; Xia et al., 2002; Xia et al., 2005). A randomized phase III study 
(EGF104900) compared the activity of lapatinib alone and in combination with trastuzumab 
in patients with HER2-positive, trastuzumab-refractory MBC. The combination treatment 
performance was superior to lapatinib alone in terms of both the PFS and the CBR 
(Blackwell et al., 2010). This was also supported by the Neoadjuvant Lapatinib and/or 
Trastuzumab Treatment Optimization (NeoALTTO) phase III randomized neoadjuvant 
study which compared lapatinib and trastuzumab both alone and in combination with 
paclitaxel for the treatment of HER2-positive primary breast cancer. pCR rates for the three 
arms were 24.7% for lapatinib alone, 29.5% for trastuzumab alone, and 51.3% for the 
combination (Baselga et al., 2010b). These results suggested that combination therapy with 
lapatinib and trastuzumab is useful for both metastatic and primary breast cancers. Brain 
metastases are common among HER2-positive MCB patients, and usually imply poor 
prognosis and short survival. Because lapatinib is a small-molecule tyrosine kinase inhibitor, 
it might be able to cross the blood–brain barrier to provide effect therapeutic concentrations 
in cerebrospinal fluid. In mice with established brain metastases, treatment with lapatinib 
significantly suppressed the growth of brain metastases (Gril et al., 2008). In clinical trials, 
lapatinib monotherapy showed modest antitumor activity against brain metastases, and 
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additional responses were observed for a combination of lapatinib and capecitabine (Lin et 
al., 2009; Metro et al., 2010; Ro et al., 2010). These data suggest that lapatinib is an effective 
therapeutic for brain metastases from breast cancer. 
2.3.2 Erlotinib 
Erlotinib is a highly potent reversible inhibitor of HER1/EGFR tyrosine kinase. It is 
activated by the extracellular binding of EGF, and is potentiated by the dimerization of 
activated receptors. Erlotinib has been shown to inhibit tumor cell growth in several human 
cancers (Moyer et al., 1997; Pollack et al., 1999). In clinical trials, erlotinib showed antitumor 
effects in patients with NSCLC, squamous cell carcinoma of the head and neck, and 
hepatocellular carcinoma (Pérez-Soler et al., 2004; Soulieres et al., 2004; Thomas et al., 2007); 
however, erlotinib monotherapy had minimal activity in patients with breast cancer (Dickler 
et al., 2009). In HER2-positive breast cancer models, the concurrent inhibition of HER2 and 
EGFR led to improved anticancer activity compared with the inhibition of HER2 alone. In 
breast cancer cell lines, trastuzumab and erlotinib demonstrated synergistic activity over a 
range of clinically relevant concentrations (Finn et al., 2003) and, in xenograft models, anti-
EGFR plus VEGF therapy showed increased activity compared with either agent alone (Jung 
et al., 2002). These results provided a rationale for combining trastuzumab or bevacizumab 
with erlotinib in clinical studies. The combination of erlotinib and trastuzumab has been 
found to be well tolerated, with four PRs achieved in 12 patients, and a time to progression 
(TTP) of 9.03 months (Britten et al., 2009). The combination of erlotinib and bevacizumab 
was examined in 38 patients with MBC, one of whom achieved a PR, 15 had stable disease at 
first evaluation (at 9 weeks), and four of these had stable disease (SD) beyond 26 weeks. 
Although this combination therapy was well tolerated, it showed limited activity in 
unselected patients with previously treated MBC (Dickler et al., 2008). Current clinical trials 
are investigating the use of combination therapy with erlotinib and oral mTOR protein 
kinase inhibitor (Everolimus) (ClinicalTrials.gov 2), hormone therapy (fulvestrant) 
(ClinicalTrials.gov 3), and chemotherapy (docetaxel) (ClinicalTrials.gov 4) for breast cancer.  
2.3.3 Gefitinib 
Gefitinib is a small-molecule anticancer agent. This selective EGFR tyrosine kinase inhibitor 
blocks the signal-transduction pathway implicated in the proliferation and survival of 
cancer cells (Albanell et al., 2002; Woodburn, 1999). Preclinical studies clearly established 
that gefitinib potently inhibits growth in various human cancer cells (Ciardiello et al., 2000; 
Sirotnak et al., 2000; Wakeling et al., 2002), and similar growth-inhibitory effects of gefitinib 
have been reported in breast cancer models (Campiglio et al., 2004; Lu et al., 2003; Moulder 
et al., 2001). A significant antitumor effect was observed in the Iressa Dose Evaluation in 
Advanced Lung Cancer (IDEAL) clinical trial, and gefitinib is now approved in several 
countries for the treatment of advanced NSCLC (Bell et al., 2005; Fukuoka, 2003). However, 
clinical trials showed that gefitinib monotherapy did not appear to be efficacious in the 
treatment of advanced MBC patients (von Minckwitz et al 2005). A phase II clinical trial 
found that gefitinib in combination with docetaxel was an active regimen for patients with 
MBC (Dennison et al., 2007). Phase II clinical trials of gefitinib in combination with either the 
non-steroidal aromatase inhibitor anastrozole or tamoxifen showed improved PFS 
(Cristofanilli et al., 2010; Osborne et al., 2011). Although combined treatment with drugs that 
target EGFR (gefitinib) and HER2 (trastuzumab) resulted in efficient inhibition of tumor 
growth in breast cancer cells that co-expressed both receptors (Normanno et al., 2002), a 
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phase I/II study showed that gefitinib in combination with trastuzumab was unlikely to 
result in clinical benefit compared with trastuzumab alone (Arteaga et al., 2008). Further 
investigation is warranted to clarify the effect of gefitinib in breast cancer patients. 
2.4 mTOR inhibitors 
PTEN exhibits tumor suppressor activity in the PI3K/Akt/mTOR signaling pathway, and 
its loss is associated with trastuzumab resistance. Everolimus (RAD001) is a rapamycin ester 
analog that inhibits mTOR, and in combination with trastuzumab, it has been reported to 
inhibit breast cancer growth in vitro and in vivo (Lu et al., 2007). These results strongly 
suggested promising results of the concomitant use of trastuzumab with mTOR inhibitor for 
treating cases of trastuzumab resistance by PTEN loss. A randomized phase II study 
evaluated patients with MBC and reported that their response rate with daily everolimus 
monotherapy was 12% (Ellard et al., 2009). Everolimus has also been studied in combination 
with chemotherapy. Combination therapy of everolimus with paclitaxel and trastuzumab in 
patients with HER2-overexpressing MBC pretreated with trastuzumab has been reported. 
The ORR of this therapy was 44% and it was generally well tolerated. When combined with 
vinorelbine and trastuzumab, everolimus exhibited an ORR of 19.1%, with a disease control 
rate of 83.0% and a median PFS of 30.7 weeks (Jerusalem et al., 2011). These clinical data 
suggested that everolimus combined with chemotherapy and trastuzumab is generally well 
tolerated and exhibits promising antitumor activity in heavily pretreated patients with 
HER2-overexpressing MBC that progressed on trastuzumab therapy. A summary of EGFR 
family signaling and target therapies for breast cancer is presented in Fig. 1. 
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Fig. 1. EGFR family signaling and target therapies for breast cancer 
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2.5 Angiogenesis pathway 
Angiogenesis is essential for tumor growth or metastasis. The primary factor controlling 
vessel formation is hypoxia, which triggers the secretion of pro-angiogenic factors, 
particularly VEGF, and stimulates new vessel formation to supply oxygen to the tumor. 
VEGF therefore plays a key role in tumor angiogenesis (Ferrara et al., 2003; Jain, 2003; 
Yancopoulos et al., 2000). It is a 34–46 KDa homodimeric glycoprotein that acts as a ligand 
for Flt-1 (VEGF receptor-1 or VEGFR-1) and KDR or Flt-2 (VEGFR-2). Under hypoxic 
conditions, the transcription factors hypoxia-inducible factor-1 alpha (HIF-1 
alphaandHIF-2 alpha are stabilized in cancer cells, then transported to the nucleus where 
they interact with HIF-beta. This complex binds to a specific sequence on the VEGF gene 
called the hypoxia response element (HRE), which stimulates VEGF gene transcription; 
VEGF protein is produced and then secreted from cancer cells (Fox et al., 2007; Shibuya, 
2001). VEGF binds to VEGFR-2, which is expressed on the endothelial cell membrane, and 
homodimerization of the latter occurs. The effects of VEGF are mediated by the activation of 
various intracellular signaling transduction pathways, such as receptor tyrosine kinase 
activity or autophosphorylation of VEGFR-2, and the receptor mediates the biological action 
via the phospholipase C (PLC)–protein kinase C (PKC)–MAPK pathway. In other words, 
PLC directly binds to the autophosphorylated VEGFR-2, is tyrosine-phosphorylated then 
activated; this stimulates the activation of PKC and the Raf-1–MAPK cascade (Shibuya, 
2001; Takahashi et al., 1999). Several preclinical studies showed that a VEGF-specific 
monoclonal antibody suppressed neovascularization and inhibited tumor growth arising 
from human cancer cell lines injected into nude mice (Fox et al., 2002; Kim et al., 1993). 
These results strongly suggest that VEGF inhibition blocks angiogenesis and tumor growth. 
The mechanism of the antitumor effect achieved through targeting VEGF might involve the 
stimulation of apoptosis of the tumor vasculature, the inhibition of metastasis, or the 
initiation of antitumor immune responses. VEGF inhibition might prevent its protective 
effect against apoptosis in tumor blood vessel-associated endothelial cells, leading to 
disruption of the tumor blood supply. In view of this antitumor activity, drugs targeting the 
VEGF system are currently in development. Mechanism of VEGF signaling is illustrated in 
figure 2. 
2.5.1 Bevacizumab 
The most promising approaches are offered by monoclonal antibodies directed against 
VEGF. Among the drugs in this class, bevacizumab, which consists of 93% human and 7% 
murine components, is currently at the most advanced stage of development. Bevacizumab 
is highly specific to VEGF-A and prevents angiogenesis by inhibiting the VEGF ligand 
thereby inhibiting VEGF signaling. Bevacizumab potently reduced the growth rate of 
several malignant tumors using xenograft models (Lee et al., 2008; Segerström et al., 2006) 
but, in a phase I/II trial, the clinical effects of bevacizumab monotherapy for breast cancer 
were unclear (Cobleigh et al., 2003); these might, however, be enhanced by using a 
combination of conventional chemotherapy and bevacizumab. The randomized phase III 
Eastern Cooperative Oncology Group 2100 (ECOG-E2100) trial compared paclitaxel with or 
without bevacizumab as first-line therapy for HER2-negative MBC; the addition of 
bevacizumab significantly increased the ORR (36.9% vs 21.2%; p<0.001) and the PFS (11.8 vs 
5.9 months; p<0.001), but not the OS (26.7 vs 25.2 months; p=0.16) (Miller et al., 2007). 
Nevertheless, first-line anti-angiogenic therapy using bevacizumab clearly improved the 
response for earlier stage MBC. The Avastin and Docetaxel (AVADO) trial compared 
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Fig. 2. Mechanisum of VEGF signaling 
docetaxel with or without bevacizumab (at 7.5 mg/kg or 15 mg/kg) as first-line therapy for 
HER2-negative MBC (Miles et al., 2009). The combination therapy significantly increased the 
PFS (8.2 months for docetaxel plus placebo, 9.0 months for docetaxel plus bevacizumab at 
7.5 mg/kg, and 10.1 months for docetaxel plus bevacizumab at 15 mg/kg), overall RR (46%, 
55%, and 64%, respectively) and 1-year survival rates (76%, 81%, and 84%, respectively). As 
described above, a stronger antitumor effect is expected when prescribing bevacizumab to 
patients at an earlier stage of MBC. Several first or second-line clinical trials using 
bevacizumab are currently ongoing. The Regimens in Bevacizumab for Breast Oncology 
(RiBBON 1) trial is a phase III study that aims to establish standard first-line chemotherapy 
regimens and is comparing paclitaxel with or without bevacizumab for 722 HER2-negative 
MBC patients, while the RiBBON 2 trial is investigating second-line therapy. In addition, 
chemotherapy (an anthracycline-based regimen, taxane, or capecitabine) plus bevacizumab 
is being compared with chemotherapy plus placebo; the estimated enrollment for this study 
is 1,200 patients, and the primary endpoint is PFS (O'Shaughnessy & Brufsky, 2008). A first-
line clinical trial using bevacizumab for triple-negative breast cancer is also ongoing. Triple-
negative breast cancer does not react to hormone therapy or trastuzumab, so the prognosis 
is poor (Sørlie et al., 2001). Chemotherapy is the only suitable current treatment, but a 
combination of chemotherapy and bevacizumab is expected to be effective. Phase II trials of 
bevacizumab in combination with other regimens are currently underway for triple-
negative MBC, these include an association with doxorubicin and carboplatin, an estimated 
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enrollment of 50 patients and PFS as the primary endpoint (ClinicalTrials.gov 5), and an 
association with paclitaxel and carboplatin, an estimated enrollment of 46, and overall RR as 
the primary endpoint (ClinicalTrials.gov 6). If a stronger antitumor effect is shown by these 
clinical trials, it will suggest that bevacizumab is a good treatment strategy for triple-
negative breast cancer. A first-line clinical trial of bevacizumab combined with other 
molecular targeting therapy is also ongoing. HER2 plays a specific role in the regulation of 
VEGF expression. A preclinical study showed a strong association between HER2 and VEGF 
(Klos et al., 2006; Konecny et al., 2004), while animal models showed superior efficacy when 
bevacizumab was combined with trastuzumab (Scheuer et al., 2006). Based on these results, 
a phase II trial of combined therapy targeting HER2-amplified MBC or local relapse, and 
surgically-unresectable breast cancer, was carried out using trastuzumab and bevacizumab 
as first-line treatment. A clinical response was documented in 13 of 28 patients (46%), all of 
whom showed a PR (Pegram 2006). These data support the clinical use of combination 
therapy with bevacizumab and trastuzumab, and suggest that it is an effective first-line 
therapy for HER2-overexpressing MBC.  
The novel targeted agents that are currently being clinically evaluated for use in breast 
cancer are expected to show promising results. We are also continuing to investigate other 
molecules that might be useful for treatment of breast cancer. Our goal is to establish the 
potential of such agents to be translated into novel and useful approaches to breast cancer 
therapy, and to move promising lead compounds rapidly from the bench to the bedside. 
The preclinical molecular-targeting strategies that we are using against breast cancer focus 
on Cap43 and YB-1, as discussed below. 
3. Cap43 
Cap43 is a 43-kD protein identical to N-myc downstream-regulated gene 1 (NDRG1) and 
differentiation-related gene-1 (Drg-1). Cap43 expression is markedly influenced by several 
stimuli, including oxidative stress, metal ions, hypoxia, phorbol esters, vitamins A and D, 
and steroids, the oncogenes N-myc and C-myc, and the tumor-suppressor genes p53 and 
Von Hippel-Lindau (VHL). Although many studies have elucidated the characteristics of 
Cap43, its exact function remains unclear. Cap43 is expressed in various organs, including 
the prostate, ovary, colon, and kidney, and its expression changes dynamically during 
postnatal development in the kidney, brain, liver, and nerves (Lachat et al., 2002; Okuda et 
al., 1999; Shimono et al., 1999; Wakisaka et al., 2003). These observations suggested that 
Cap43 may be involved in normal organ maturation and differentiation. Cap43 expression 
has been reported to be higher than that in normal tissue in many types of human tumors, 
including colon, breast, prostate, kidney, liver, and brain cancers (Cangul et al., 2002). On 
the other hand, Cap43 expression is upregulated in normal cells and highly differentiated 
cancer cells, but downregulated in poorly differentiated cancer cells present in colon and 
prostate tumors (Bandyopadhyay et al., 2003; Guan et al., 2000). Although the exact function 
of Cap43 in malignant cells also remains unknown, a variety of studies has recently 
reported. In prostate cancer, Cap43 could be a novel marker for malignant progression and 
poor prognosis and is closely associated with the downregulation of E-cadherin expression 
(Song et al., 2010). In gastric cancer, Cap43 plays a significant role in carcinogenesis and in 
preventing metastasis and invasion (Jiang et al., 2010; Liu et al., 2010). Further, Cap43 
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enhanced portal vein invasion and intrahepatic metastasis in human hepatocellular 
carcinoma and the Cap 43 expression was thought to accelerate tumor invasion and 
metastasis (Akiba et al., 2008). In breast cancer, overexpression of the Cap43 gene inhibited 
cell growth and metastasis, and low Cap43 expression in breast cancer cells is closely 
correlated with poor clinical outcomes (Bandyopadhyay et al., 2004). These results indicate 
that one of the roles of Cap43 is suppression of metastasis; further, the Cap43 expression 
levels could serve as a good predictor of survival in breast cancer. Furthermore, Fotovati et 
al. (2011) reported that the endogenous Cap43 expression level was closely correlated with 
the differentiation status of breast cancer cell lines and that Cap43 overexpression expanded 
the differentiated areas in the xenograft model of breast cancer. Immunohistochemical 
analysis of human breast cancer specimens showed a close relationship between Cap43 and 
beta-casein or milk fat protein, which is a differentiation marker of breast tissue. Therefore, 
Cap43 is closely associated with the differentiation and/or malignant states of breast 
cancers. As reported in previous studies, the Cap43 gene could play a key role in breast 
cancer. Therefore, in order to assess the potential of Cap43 as a molecular target for the 
effects of anti-estrogenic agents in breast cancer, we investigated Cap43 gene expression 
during therapeutic treatment with anti-estrogenic drugs. Of the 8 breast cancer cell lines we 
examined, 4 expressed high levels of Cap43 and very low levels of estrogen receptor 
alpha(ER alpha) and the remaining 4 expressed low levels of Cap43 and high ER alpha 
levels. Estradiol (E2) treatment reduced Cap43 expression in a dose-dependent fashion in ER 
alpha-positive cell lines, but did not affect the expression in ER alpha-negative lines. 
Administration of the 2 anti-estrogenic agents tamoxifen and ICI 182780 inhibited the E2-
induced downregulation of Cap43. Overexpression of ER alpha in the ER alpha-negative cell 
lines SKBR-3 and MDA-MB-231 resulted in the downregulation of Cap43. Immunostaining 
revealed that Cap43 expression was inversely correlated with the expression of ER alpha. 
The E2-induced downregulation of Cap43 appears to be mediated through ER alpha-
dependent pathways in breast cancer cells, both in culture and in patients (Fotovati et al., 
2006). Since Cap43 expression was very sensitive to E2 and/or anti-estrogens in ER alpha-
positive breast cancer cells, it is a potential molecular marker for determining the 
therapeutic efficacy of anti-estrogenic agents in breast cancer. In breast cancer therapy, 
when ER alpha(+) Cap43(–) patients are treated with tamoxifen, resulting in upregulation of 
Cap43, tamoxifen appears to be effective and the treatment should be continued. However, 
if Cap43 is not upregulated following tamoxifen administration in ER alpha(+) Cap43(-) 
patients, tamoxifen can be deemed ineffective, and the treatment should be changed. The 
postoperative blood Cap43 level can be easily measured; however, Cap43 is not a secreted 
protein. This poses clinical problems; to overcome these, we are currently exploring proteins 
that might be associated with Cap43. If the protein associated with Cap43 is identified, the 
Cap43 levels can be indirectly obtained by measuring the levels of this protein. Further 
studies are required in order to use Cap43 in clinical trials. 
4. YB-1 
YB-1 belongs to the cold shock domain protein family, members of which are found in both 
the cytoplasm and nucleus of human cells. It has pleiotropic functions in the regulation of 
gene transcription and translation, DNA repair, drug resistance, and cellular responses to 
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environmental stimuli (Izumi et al., 2001; Kohno et al., 2003; Kuwano et al., 2003). YB-1 is 
normally present in the cytoplasm, although it is translocated to the nucleus when cells are 
exposed to anticancer drugs or ultraviolet (UV) light (Koike et al., 1997; Uchiumi et al., 1993). 
Nuclear localization of YB-1 is required for its transcriptional control of multidrug resistance 
(MDR)-related genes and for the control of repair of DNA damage caused by  
anticancer agents or radiation in cancer cells, resulting in the acquisition of global drug 
resistance to a wide range of anticancer agents (Kohno et al., 2003; Kuwano et al., 2004). 
Nuclear translocation of YB-1 is controlled by PKC and related proteins, protein tyrosine 
phosphatase, JAK1, and Akt (Basaki et al., 2007; Dooley et al., 2006; Koike et al., 1997; 
Sorokin et al., 2005; Stenina et al., 2000; Sutherland et al., 2005). Immunohistochemical 
labeling experiments have revealed that nuclear YB-1 expression was correlated with the 
expression of a representative MDR-related ATP-binding cassette superfamily protein, P-
glycoprotein, which is encoded by the MDR1/ABCB1 gene; moreover, other drug 
resistance-related molecules have been reported in tumor specimens from a variety of 
cancers other than breast cancer (Bargou et al., 1997; Giménez-Bonafé et al., 2004; Janz et al., 
2002; Kamura et al., 1999; Oda et al., 1998; Saji et al., 2003). In contrast, nuclear expression of 
YB-1 is often associated with a poor prognosis in various human malignancies, including 
breast cancer (Bargou et al., 1997; Dahl et al., 2009; Janz et al., 2002), ovarian cancer (Kamura 
et al., 1999), synovial sarcoma (Oda et al., 2003), and lung cancer (Shibahara et al., 2001). 
These findings strongly suggested that the nuclear expression of YB-1 can be used as a 
predictor in some human malignancies. Furthermore, the YB-1 gene was able to induce 
breast cancer in experimental animal models, suggesting its role as an oncogene that 
promotes the breast cancer progression (Bergmann et al., 2005). Additionally, YB-1 
overexpression in human mammary epithelial cells can induce an EGF-independent growth 
phenotype through activation of the EGFR pathway (Berquin et al., 2005). Knockdown of 
YB-1 inhibited breast cancer cell growth and it is thought to be involved in the induction of 
apoptosis via the mTOR/STAT3 intracellular signaling pathway (Fujii et al. 2009, Lee et al., 
2008). These studies all suggest a close linkage between YB-1 expression and the growth or 
proliferation potential of cancer cells via intracellular signaling, and indicate its association 
with poor prognosis of patients with breast cancer. Since YB-1 might play its key role not 
only by controlling the expression of drug resistance-related genes but also the expression of 
cell growth-related genes, we investigated the association of YB-1 localization to the nucleus 
with the expression of EGFR family proteins, hormone receptors, and other molecules 
whose expressions are probably associated with poor prognosis in patients with breast cancer. 
Knockdown of YB-1 with siRNA significantly reduced the expression levels of EGFR, HER2, 
and ER alpha in ER alpha-positive but not ER alpha-negative breast cancer cell lines. Nuclear 
YB-1 expression was positively correlated with HER2 (P = 0.0153) and negatively correlated 
with ER alpha (P = 0.0122) and chemokine (C-X-C motif) receptor 4 (CXCR4: which is known 
to play a critical role in the growth and metastasis of human breast cancers(Müller A et al., 
2001, Liang, Z et al., 2004)) (P = 0.0166) in human breast cancer clinical specimens; however, it 
was not correlated with EGFR expression. Nuclear YB-1 expression was an independent 
prognostic factor for the overall (P = 0.0139) and progression-free (P = 0.0280) survival in these 
patients. These data strongly suggested that nuclear YB-1 localization could be a molecular 
target of intrinsic importance in not only the acquisition of multidrug resistance but also tumor 
growth dependent on HER2 and other growth factor receptors in breast cancer (Fujii et al., 
2008). Intracellular signaling via Cap43 and YB-1 is illustrated in Fig. 3. 
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5. Conclusion 
The development of effective adjuvant therapy, based on the post-operative administration 
of chemotherapy, hormone therapy, or trastuzumab, has significantly improved survival 
among breast cancer patients. However, therapy for adjuvant-resistant or metastatic disease 
is still palliative, and the possibility of inducing complete remission or a definitive cure for 
breast cancer remains remote. The research effort so far has identified key selective changes 
in molecules such as Cap43 and YB-1 that sustain breast cancer growth and progression. 
This provides the potential to develop specific, targeted therapies as the next generation of 
anticancer therapeutics. 
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